University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title

Assessing Treatment for Patients with Pulmonary Arterial Hypertension


AMBITION: A Randomised, Multicenter Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) 

The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial Hypertension. This will be assessed by time to the first clinical failure event.


This trial is closed to enrollment,

Please refer to identifier NCT01178073 for more information.

Start Date
August 10, 2007
End Date
January 31, 2015
Gender Preference
Age Group
18 - 75 years
Principal Investigator
Sif Hansdottir, MD
Contact Info

Pulmonary Hypertension Program

Page Scovel, RN

Phone:  319-385-8005

Fax:  319-356-7087

Department or Field of Study
Heart ; high blood pressure in lungs ; PAH ; PH ; Pulmonary arterial hypertension ; Pulmonary diseases ; Pulmonary hypertension ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.